Investors
Life Sciences Partners (LSP) is a leading European venture capital firm, providing private equity capital to life sciences companies. Based in Amsterdam and Munich, LSP's management has focused on investing in human life sciences since 1988. Typically, LSP is actively involved in building value as lead investor and board member. LSP has invested in more than 30 life science companies and has achieved 12 successful exits, i.e. Rhein Biotech (NL), Qiagen (DE), Biora (SE), Quadrant (GB), Sequenom (DE/USA) and Crucell (NL). LSP currently has € 170 million in capital under management.
Dr. Joachim Rothe, responsible for LSP´s Munich office, represents the firm on Affectis´ Supervisory Board.
www.lspvc.com
EMBL Ventures is an early stage life-science investor currently managing about € 26 million on behalf of major institutional and private investors. It is the primary venture vehicle of the European Molecular Biology Laboratory (EMBL) in Heidelberg/Germany. EMBL Ventures profits from the unique scientific excellence of the EMBL and from the strengths of its limited partners. The objective of the fund is financial return; it is not a strategic fund. With several years experience in early stage investing, EMBL Ventures provides long-term equity financing to entrepreneurs to build and strengthen their companies and to realize their company vision. EMBL Ventures typically leads A and B rounds and works closely together with other venture capital firms either from it’s own network or from outside.
Dr. Christoph Antz, Managing Director, represents the firm on Affectis´ Supervisory Board.
www.embl-ventures.com
further investors
Life Sciences Partners (LSP) is a leading European venture capital firm, providing private equity capital to life sciences companies. Based in Amsterdam and Munich, LSP's management has focused on investing in human life sciences since 1988. Typically, LSP is actively involved in building value as lead investor and board member. LSP has invested in more than 30 life science companies and has achieved 12 successful exits, i.e. Rhein Biotech (NL), Qiagen (DE), Biora (SE), Quadrant (GB), Sequenom (DE/USA) and Crucell (NL). LSP currently has € 170 million in capital under management.
Dr. Joachim Rothe, responsible for LSP´s Munich office, represents the firm on Affectis´ Supervisory Board.
www.lspvc.com
EMBL Ventures is an early stage life-science investor currently managing about € 26 million on behalf of major institutional and private investors. It is the primary venture vehicle of the European Molecular Biology Laboratory (EMBL) in Heidelberg/Germany. EMBL Ventures profits from the unique scientific excellence of the EMBL and from the strengths of its limited partners. The objective of the fund is financial return; it is not a strategic fund. With several years experience in early stage investing, EMBL Ventures provides long-term equity financing to entrepreneurs to build and strengthen their companies and to realize their company vision. EMBL Ventures typically leads A and B rounds and works closely together with other venture capital firms either from it’s own network or from outside.
Dr. Christoph Antz, Managing Director, represents the firm on Affectis´ Supervisory Board.
www.embl-ventures.com
further investors